Geron Sees RYTELO Revenue Near High End of 2026 Guidance as Community Use Expands

Geron expects RYTELO’s 2026 revenue near the high end of its $230 million–$240 million guidance , supported by three consecutive quarters of growth, a 24% first-half revenue increase, and lower operating expenses.

The company is expanding RYTELO use in community treatment settings and prioritizing second-line, earlier treatment of lower-risk MDS, where about 80% of patients are treated in the community.

Geron is reviewing partnership and commercial options for Europe, while preserving capital flexibility; it reported more than $320 million in cash and continues regulatory discussions on its myelofibrosis study.

Geron Corporation: FDA Approval Fuels Stock Price Surge

Geron NASDAQ: GERN said it expects full-year net revenue from RYTELO to land in the mid-to-high end of its previously stated range, or approximately $230 million to $240 million, as the company continues to expand use of the telomerase inhibitor in lower-risk myelodysplastic syndromes, or MDS.

During the Cantor Healthcare Conference, Chief Executive Officer Harout Semerjian said Geron generated $57.5 million in net revenue during the second quarter, nearly $5 million above the preceding quarter.

He said the company has now recorded three consecutive quarters of growth and reported that RYTELO revenue rose 24% in the first half of the year while operating expenses declined 4%.

“We definitely see a path to profitability,” Semerjian said, noting that Geron’s revenue outlook and operating-expense guidance are both in the $230 million to $240 million range.

However, he said the company is also focused on building a broader business and maintaining financial flexibility for future opportunities.

Community Expansion and Earlier-Line Use

Semerjian said Geron’s commercial strategy has progressed from early engagement with academic medical centers toward greater penetration of community treatment settings. He said roughly 80% of lower-risk MDS patients are seen and treated in the community, particularly those in the second-line population targeted by RYTELO.

Geron is focusing on high-volume community accounts and on increasing use within accounts that have already adopted the treatment.

Semerjian characterized this as a shift toward “depth” of use while the company continues to add new accounts.

The company is also seeking to move utilization toward earlier treatment lines.

Semerjian said more than one-third of patients receiving RYTELO are now coming from earlier lines of therapy.

He said Geron’s label and recently updated NCCN guidelines support use in the second-line setting, where the company believes its data are strongest and treatment duration may be longer than in later-line use.

While physicians may continue to use the therapy organically in later-line patients, Semerjian said Geron’s commercial efforts will center on second-line treatment.

European Strategy Under Review

Geron has global rights to RYTELO and has received European Medicines Agency approval.

Semerjian said the company plans to update investors by the end of the year on its strategy for markets outside the United States, including Europe.

Potential approaches could include partnerships, targeted commercial activity or use of contract sales organizations, he said.

Geron does not plan to pursue a traditional model of building large country-by-country commercial teams in Europe.

Semerjian said the company is weighing pricing and policy considerations, including the evolving most-favored-nation, or MFN, discussion.

He said management intends to preserve its flexibility and avoid making decisions that could un...